In cooperation with the Food and Drug Administration (FDA), and as a service to our members, we will periodically distribute information about newly approved therapies or significant changes to approved therapies. This helps FDA to inform professionals in patient care arena of recent approvals in a timely manner. Included in the email from the FDA is a link to the product label, which will provide the relevant clinical pharmacology information on the indication, contraindications, dosing, and safety. In sending this information, we do not endorse any product or therapy and do not take any position on the safety or efficacy of the product or therapy described.
FDA Expands Kalydeco (Ivacaftor)
FDA Approves IMFINZI™ (Durvalumab)
FDA Approves RYDAPT® (Midostaurin)
FDA Approves DUPIXENT (Dupilumab)
FDA Approves OCREVUS (Ocrelizumab)
FDA Approves ALUNBRIG (Brigatinib)
FDA Approves ZEJULA (niraparib)
FDA Approves BAVENCIO (avelumab)
FDA Approves KISQALI (ribociclib)
FDA Approves SPINRAZA
FDA Announces Availability of the Guidance, "Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product"
FDA Approves RUBRACA™
FDA Announces Availability of the Draft Guidance,"Physiologically Based Pharmacokinetic Analyses-Format and Content"
2016 FDA Bursts